Marketing-authorisation holder · Spain
Instituto Grifols S.A.
111 medicines in 9 countries, as authorisation holder, manufacturer and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Spain
111 medicines in 9 countries, as authorisation holder, manufacturer and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 111
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALBUMINA GRIFOLSSoluzione per infusione | Albumin | Italy | Authorised | |
| ALBUMINA UMANA GRIFOLSSoluzione per infusione | Albumin | Italy | Authorised | |
| ALBUPLAN 200 G/L SOLUCION PARA PERFUSION0.200 g · Solución para perfusión | Albumin | Spain | Marketed | 2019 |
| ALBUPLAN 50 G/L SOLUCIÓN PARA PERFUSIÓN0.050 g · Solución para perfusión | Albumin | Spain | Authorised | 2019 |
| Albutein 200 g/l otopina za infuzijuOtopina za infuziju | Albumin | Croatia | Authorised | 2026 |
| ALBUTEIN 200 G/L SOLUCIÓN PARA PERFUSIÓN200 mg · Solución para perfusión | Albumin | Spain | Marketed | 1968 |
| Albutein 50 g/l otopina za infuzijuOtopina za infuziju | Albumin | Croatia | Authorised | 2026 |
| ALBUTEIN 50 G/L SOLUCIÓN PARA PERFUSIÓN50 mg · Solución para perfusión | Albumin | Spain | Marketed | 1968 |
| ANBINEXPolvere e solvente per soluzione per infusione endovenosa | Antithrombin iii | Italy | Authorised | |
| ANBINEX POLVO Y DISOLVENTE PARA SOLUCION PARA PERFUSION50 ui · Polvo y disolvente para solución para perfusión | Antithrombin iii | Spain | Marketed | 1992 |
| FACTOR IX GRIFOLS 50 UI/ml POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE40 - 62,5 UI + 0,2 - 0,6 mg · Polvo y disolvente para solución inyectable | Coagulation factor ix, Proteínas | Spain | Marketed | 2004 |
| FANHDIPolvere e solvente per soluzione iniettabile | Antihemophilic factor, Fattore von willebrand | Italy | Authorised | |
| Fanhdi 100 IU/ml (1000 IU/10 ml i 1500 IU/15 ml) prašak i otapalo za otopinu za injekciju/infuzijuPrašak i otapalo za otopinu za injekciju / infuziju | Antihemophilic factor, Von willebrandov faktor, ljudski | Croatia | Authorised | 2019 |
| FANHDI 100 UI FVIII/120 UI FVW POR ml POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE100 ui + 120 ui · Polvo y disolvente para solución inyectable | Factor vii, Von willebrand factor | Spain | Marketed | 1994 |
| Fanhdi 25 IU/ml prašak i otapalo za otopinu za injekciju/infuzijuPrašak i otapalo za otopinu za injekciju / infuziju | Antihemophilic factor, Von willebrandov faktor, ljudski | Croatia | Authorised | 2019 |
| FANHDI 25 UI FVIII/30 UI FVW POR ml POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE250 ui + 300 ui · Polvo y disolvente para solución inyectable | Factor vii, Von willebrand factor | Spain | Marketed | 1994 |
| Fanhdi 50 IU/ml prašak i otapalo za otopinu za injekciju/infuzijuPrašak i otapalo za otopinu za injekciju / infuziju | Antihemophilic factor, Von willebrandov faktor, ljudski | Croatia | Authorised | 2019 |
| FANHDI 50 UI FVIII/60 UI FVW POR ml POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE500 ui + 600 ui · Polvo y disolvente para solución inyectable | Factor vii, Von willebrand factor | Spain | Marketed | 1994 |
| FLEBOGAMMA 10%100 mg / ml · Solution | Immunoglobulin | Canada | Authorised | |
| FLEBOGAMMA 5%50 mg / ml · Solution | Immunoglobulin | Canada | Authorised | |
| Flebogamma 5%, Flebogamma 5% Dif10g/200ml · Injection | Immune globulin intravenous | United States | Marketed | 2003 |
| Flebogamma 5%, Flebogamma 5% Dif5g/50ml · Injection | Immune globulin intravenous | United States | Not marketed | 2010 |
| Flebogamma 5%, Flebogamma 5% Dif20g/200ml · Injection | Immune globulin intravenous | United States | Not marketed | 2010 |
| Flebogamma 5%, Flebogamma 5% Dif10g/100ml · Injection | Immune globulin intravenous | United States | Not marketed | 2010 |
| Flebogamma 5%, Flebogamma 5% Dif2.5g/50ml · Injection | Immune globulin intravenous | United States | Not marketed | 2003 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 34 | 32 | 2 | CompaniesAll medicines |
| Saudi Arabia | 20 | 20 | 0 | CompaniesAll medicines |
| United States | 16 | 16 | 0 | CompaniesAll medicines |
| Italy | 15 | 15 | 0 | CompaniesAll medicines |
| Canada | 7 | 7 | 0 | CompaniesAll medicines |
| Netherlands | 6 | 6 | 0 | CompaniesAll medicines |
| Croatia | 5 | 5 | 0 | CompaniesAll medicines |
| European Union (EMA) | 4 | 3 | 1 | CompaniesAll medicines |
| Romania | 4 | 0 | 4 | CompaniesAll medicines |
Also in the registers of Brazil, France, Serbia, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.